| VRT |
Report |
Adj. diluted EPS (Q2'26) |
BEAT |
pred ~$1.52 vs. cons ~$1.43 |
HIGH |
| VRT |
Report |
Net sales (Q2'26) |
BEAT |
pred ~$3.46B vs. cons ~$3.39B |
MEDIUM |
| VRT |
Report |
Adj. operating margin (Q2'26) |
BEAT |
pred ~22.4% vs. cons ~21.6% |
MEDIUM |
| VRT |
Guide |
FY26 adj. EPS guide (raise) |
BETTER |
guide ~$6.55-6.65 vs. cons ~$6.45 (FY2026) |
MEDIUM |
| VRT |
Guide |
FY26 net sales guide (raise) |
BETTER |
guide ~$13.9-14.2B vs. cons ~$13.85B (FY2026) |
MEDIUM |
| VRT |
Guide |
Orders/book-to-bill & pipeline commentary |
BETTER |
pred orders up ~mid-20s% YoY, TTM book-to-bill ~1.2x vs. cons ~up ~high-teens%/~1.1x (Q2'26/2027 visibility) |
MEDIUM |
| VRT |
Guide |
EMEA organic growth H2 inflection |
BETTER |
pred Q2 organic ~-5% improving to positive in H2 vs. cons ~-15% (Q2'26/H2'26) |
LOW |
| VRT |
Guide |
Q3'26 revenue guide |
BETTER |
guide ~$3.7B vs. cons ~$3.6B (Q3'26) |
LOW |
| VRT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+7.5% |
— |
MEDIUM |
| VRT |
Return |
5-day cumulative residual |
+9.0% (FOLLOW-THROUGH) |
Washed-out positioning (stock -25% off highs, -6% day before print) plus a clean beat-and-raise with orders/pipeline up YoY drives positive estimate revisions and out-period EPS/margin marks higher, supporting follow-through as short covering and relief buying persist. Risk is a partial fade given ~42x forward multiple and fragile AI-capex sentiment, but upward revisions and credible H2 acceleration/EMEA inflection should keep the residual net positive. |
LOW |